상세 보기
초록
Nitazoxanide-based analogues were synthesized and evaluated for HBx-DDB1 interaction inhibition using a split-luciferase assay. Compared to the nitazoxanide (NTZ, IC50 = 1.2 mu M) the compound 49a exhibited potent inhibition of the HBx-DDB1 interaction with an IC50 of 0.083 mu M. Consistent with its HBx-DDB1 inhibitory effect, compound 49a showed antiviral activity in HBV-infected cells. Compound 49a displayed excellent metabolic stability in human liver microsomes (82% remaining after 30 min), minimal hERG inhibition, and limited CYP interference, showing only moderate inhibition of CYP2C9. In vivo pharmacokinetic studies in mice and rats revealed rapid absorption (T-max = 0.5-3.5 h), low systemic clearance (0.09-0.10 L/h/kg), and high oral bioavailability (>90%). These findings establish compound 49a as a promising lead for the development of direct-acting antivirals targeting chronic HBV infection.
키워드
- 제목
- Synthesis of Nitazoxanide Derivatives as Potent and Orally Available HBx-DDB1 Inhibitors against Hepatitis B Virus
- 저자
- Kim, Seong Gon; Cha, Hyeon-Min; Kim, Minwoo; Jo, Inseong; Han, Soo Bong; Kim, Meehyein; Park, Wonseo; Kim, Youyoung; Ko, Chunkyu; Kim, Dong-Su
- 발행일
- 2026-06
- 유형
- Article; Early Access
- 권
- 17
- 호
- 7
- 페이지
- 1539 ~ 1546
- 언어
- ENG
- 출판사
- AMER CHEMICAL SOC
- 발행국가
- 미국
- 분량
- 8 페이지
- ISSN
- E 1948-5875
P 1948-5875